



Randomization
working group

Dear all,

We are pleased to announce a call for manuscripts for a special issue of *Statistics in Biopharmaceutical Research* (SBR), an Official Journal of the American Statistical Association, dedicated to the 2021 Workshop.

Members of the [NISS Ingram Olkin Forum](#) on Randomization Tests to Address Clinical Trial Disruptions, the members of the randomization working group, and the general scientific community are invited to apply. **The paper must focus on topics related to randomization in clinical trials.** Submissions pertaining to the use of randomization to address clinical trial disruptions are welcome.

Manuscripts should be submitted online at ScholarOne Manuscripts System <https://mc.manuscriptcentral.com/statsbr>. Once you login to the system, go to the “Start New Submission” page. Please select “RRDART” at “Step 1: Type, Title, & Abstract”. Manuscripts can be submitted until **March 31, 2022**. Please **note that there is no guarantee of acceptance for a submission**. All papers will be peer-reviewed, according to the reviewing principles of SBR. Accepted papers will be published continuously online on the journal website (as soon as accepted) and will be listed together in the special issue.

A guide for authors and other relevant information for submission of manuscripts is available on the “Instructions for Authors” page at the journal website <https://www.tandfonline.com/toc/usbr20/current> and “ASA Style Guide” page at ASA-Taylor and Francis website <https://amstat.tfjournals.com/asa-style-guide/>

Manuscripts are accepted in Word or LaTeX, though LaTeX is preferred. The LaTeX template is available here: <https://www.tandfonline.com/action/authorSubmission?journalCode=usbr20&page=instructions>

If you have any questions, please do not hesitate to reach out to Diane Uschner (uschner@bsc.gwu.edu), Oleksandr Sverdlov (alex.sverdlov@novartis.com), Jonathan Chipman (Jonathan.Chipman@hci.utah.edu) or Toshimitsu Hamasaki (thamasaki@gwu.edu, Editor of Statistics in Biopharmaceutical Research).

Best regards,
Diane Uschner, Jonathan Chipman, Oleksandr Sverdlov, and Bill Rosenberger

Guest Associate Editors for the Special Issue on Randomization in Clinical Trials